Hematologic Oncology Update cover art

All Episodes

Hematologic Oncology Update — 148 episodes

#
Title
1

Chronic Lymphocytic Leukemia — 5-Minute Journal Club: Microlearning Activity 1

2

Chronic Lymphocytic Leukemia — Rapid Case Review: Microlearning Activity 2

3

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

4

For Oncology Nurses: Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Proceedings from the 2026 Annual ONS Congress

5

Novel Therapies for Non-Hodgkin Lymphoma — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting

6

Acute Myeloid Leukemia — Fifth Annual National General Medical Oncology Summit

7

Myelofibrosis and Systemic Mastocytosis — Fifth Annual National General Medical Oncology Summit

8

Multiple Myeloma — Fifth Annual National General Medical Oncology Summit

9

Chronic Lymphocytic Leukemia — Fifth Annual National General Medical Oncology Summit

10

Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Fifth Annual National General Medical Oncology Summit

11

Bruton Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances

12

CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson

13

Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review

14

CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson

15

Immune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 Review

16

CD19 x CD3 BiTEs for Acute Lymphoblastic Leukemia — An Interview with Dr Bijal Shah

17

Chronic Lymphocytic Leukemia — An Interview with Prof Constantine Tam on Key Presentations from the 2025 ASH Annual Meeting

18

Immune Thrombocytopenia — Microlearning Activity 2 with Dr Hanny Al-Samkari: ASH 2025 Review

19

Immune Thrombocytopenia — Microlearning Activity 1 with Dr Hanny Al-Samkari: ASH 2025 Review

20

Multiple Myeloma: Inside the Issue of Cereblon E3 Ligase Modulators

21

Relapsed/Refractory Multiple Myeloma — Microlearning Activity 2 with Dr Sagar Lonial: ASH 2025 Review

22

Immune Thrombocytopenia — ASH 2025 Review

23

Relapsed/Refractory Multiple Myeloma — Microlearning Activity 1 with Dr Sagar Lonial: ASH 2025 Review

24

Bispecific Antibodies in the Management of Lymphoma — ASH 2025 Review

25

Relapsed/Refractory Multiple Myeloma — ASH 2025 Review

26

Follicular Lymphoma and Diffuse Large B-Cell Lymphoma — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition

27

Myelofibrosis and Systemic Mastocytosis — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition

28

Chronic Lymphocytic Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition

29

Acute Myeloid Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition

30

Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Partnership with the American Oncology Network

31

CAR T-Cell Therapy for Non-Hodgkin Lymphoma | Cancer Q&A — Discussing Common Questions Posed by Patients

32

Toxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew Lunning

33

Patient Education Resource: Non-Hodgkin Lymphoma — Clinical Experts Address Common Questions Posed by Patients About CAR T-Cell Therapy

34

Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute

35

Acute Myeloid Leukemia — An Interview with Dr Eunice S Wang to Review Key Presentations from ASCO and EHA

36

Non-Hodgkin Lymphoma — The Implications of Recent Datasets for Current and Future Disease Management

37

Follicular Lymphoma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual Meeting

38

Acute Myeloid Leukemia — An Interview with Dr Ghayas Issa on the Role of Menin Inhibitors

39

Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual Meeting

40

Oncology Nursing Update: Multiple Myeloma — An Interview with Dr Beth Faiman on CAR T-Cell Therapy

41

Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management

42

Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event Management

43

Oncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Ms Charise Gleason

44

Oncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Prof Xavier Leleu

45

Relapsed/Refractory Multiple Myeloma — Oncology Q&A: Discussing Common Questions Posed by Patients

46

Multiple Myeloma | Oncology Q&A — Patient Education Resource: Clinical Experts Address Common Questions Posed by Patients with Relapsed/Refractory Multiple Myeloma

47

Acute Myeloid Leukemia — An Interview with Dr Jorge Cortes on Optimal Management of FLT3 and IDH1/2 Mutations

48

Multiple Myeloma — Optimizing the Selection of First-Line Therapy

49

Chronic Lymphocytic Leukemia — Proceedings from a Session Held During the 2025 ASCO Annual Meeting

50

Multiple Myeloma — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual Meeting

51

For Oncology Nurses: Chronic Lymphocytic Leukemia — Proceedings from the 2025 Annual ONS Congress

52

Non-Hodgkin Lymphoma — Proceedings from a Session Held During the 2025 ASCO Annual Meeting

53

For Oncology Nurses: Non-Hodgkin Lymphoma — Proceedings from the 2025 Annual ONS Congress

54

For Oncology Nurses: Chronic Myeloid Leukemia — Proceedings from the 2025 Annual ONS Congress

55

IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies

56

Multiple Myeloma — Year in Review Series on Relevant New Datasets and Advances

57

Myelofibrosis — Year in Review Series on Relevant New Datasets and Advances

58

Non-Hodgkin Lymphoma — Year in Review Series on Relevant New Datasets and Advances

59

Systemic Mastocytosis and Myelofibrosis — Fourth Annual National General Medical Oncology Summit

60

Multiple Myeloma — Fourth Annual National General Medical Oncology Summit

61

Multiple Myeloma — An Interview with Dr Rafael Fonseca on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting

62

Chronic Lymphocytic Leukemia — An Interview with Dr Lindsey Roeker on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting

63

Relapsed/Refractory Follicular Lymphoma Part 3 — A Roundtable Discussion on the Selection and Sequencing of Other Novel Therapies

64

Non-Hodgkin Lymphoma — An Interview with Dr Jennifer Crombie on the Use of Bispecific Antibodies

65

Relapsed/Refractory Follicular Lymphoma Part 2 — A Roundtable Discussion on the Selection and Sequencing of CAR T-Cell Therapy

66

Non-Hodgkin Lymphoma — Fourth Annual National General Medical Oncology Summit

67

Non-Hodgkin Lymphoma — An Interview with Dr John P Leonard on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting

68

Chronic Lymphocytic Leukemia — Year in Review Series on Relevant New Datasets and Advances

69

Immune Thrombocytopenia — A Roundtable Discussion on Current and Future Management Strategies

70

Relapsed/Refractory Follicular Lymphoma Part 1 — A Roundtable Discussion on the Selection and Sequencing of Bispecific Antibodies

71

Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 2

72

Myelofibrosis — An Interview with Dr Raajit K Rampal on Key Presentations from the 66th American Society of Hematology (ASH) Annual Meeting

73

Chronic Lymphocytic Leukemia — Fourth Annual National General Medical Oncology Summit

74

Chronic Lymphocytic Leukemia — An Interview with Dr Catherine C Coombs on Real-World Cases and Current Questions and Controversies Presented at Recent Conferences

75

For Oncology Nurses: Bispecific Antibodies in Multiple Myeloma — An Interview with Dr Tiffany A Richards

76

Oncology Nursing Update Special 2-Part Edition: Bispecific Antibodies in Lymphoma — Part 1

77

Relapsed/Refractory Diffuse Large B-Cell Lymphoma — A Roundtable Discussion on Current and Future Management Strategies

78

Multiple Myeloma — An Interview with Dr Surbhi Sidana on Optimizing the Role of CAR T-Cell Therapy

79

Multiple Myeloma — Optimizing the Selection of First-Line Therapy with Dr Saad Zafar Usmani

80

Chronic Lymphocytic Leukemia with Dr Jennifer Woyach: Part 3 of a 3-Part Meet The Professor Series

81

Data + Perspectives: Clinical Investigators Discuss the Role of CAR T-Cell Therapy for Patients with Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

82

CAR T-Cell and Bispecific Therapy for Lymphoma — Part 3 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

83

Myelofibrosis — Part 4 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

84

Chronic Myeloid Leukemia — Part 1 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

85

Acute Myeloid Leukemia — Part 5 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

86

Multiple Myeloma — Part 6 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

87

Chronic Lymphocytic Leukemia — Part 2 of Our 6-Part ASH 2024 Friday Satellite Symposia Series

88

Cases from the Community: Integrating New Research Findings into Current Practice — Myelofibrosis

89

Cases from the Community: Integrating New Research Findings into Current Practice — Leukemia and Myelodysplastic Syndromes

90

Practical Perspectives: Investigators Discuss the Current Management of Paroxysmal Nocturnal Hemoglobinuria

91

Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Multiple Myeloma

92

Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 2 of a 3-Part Series

93

Data + Perspectives: Clinical Investigators Explore the Application of Recent Datasets in Current Oncology Care  — Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

94

What Clinicians Want to Know About the Current and Future Role of EZH1/2 Inhibitors in the Care of Patients with Lymphoma

95

Practical Perspectives: Optimizing the Role of BTK Inhibitors in the Management of Mantle Cell Lymphoma

96

Practical Perspectives: Current Management of Chronic Myeloid Leukemia

97

Oncology Today with Dr Neil Love: Peripheral T-Cell Lymphoma

98

Meet The Professor: Optimizing the Management of Chronic Lymphocytic Leukemia — Part 1 of a 3-Part Series

99

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma

100

RTP Live from Chicago: Investigator Perspectives on the Role of Bispecific Antibodies in the Management of Lymphoma

101

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Myelofibrosis

102

Oncology Today with Dr Neil Love: Key Presentations on Lymphoma from Recent Major Conferences

103

Oncology Today with Dr Neil Love: Recent Advances in the Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

104

Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Multiple Myeloma

105

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia

106

Meet The Professor: Optimizing the Management of Myelofibrosis — Part 2 of a 2-Part Series

107

Striving for Consensus: Current and Future Management of Paroxysmal Nocturnal Hemoglobinuria

108

Oncology Today with Dr Neil Love: Key Presentations on Myeloproliferative Neoplasms from Recent Major Conferences

109

Oncology Today with Dr Neil Love: Key Presentations on Chronic Lymphocytic Leukemia from Recent Major Conferences

110

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Lymphoma

111

Meet The Professor: Optimizing the Management of Myelofibrosis — Part 1 of a 2-Part Series

112

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia

113

Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 3 of a 3-Part Series

114

Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 2 of a 3-Part Series

115

Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 1 of a 3-Part Series

116

What Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell Lymphoma

117

Oncology Today with Dr Neil Love: Key Presentations on Multiple Myeloma from Recent Major Oncology/Hematology Conferences

118

Oncology Today with Dr Neil Love: Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma with Dr Matthew Matasar

119

What Clinicians Want to Know About Anti-CD38 Antibodies in the Management of Multiple Myeloma

120

Oncology Today with Dr Neil Love: Blastic Plasmacytoid Dendritic Cell Neoplasm

121

Oncology Today with Dr Neil Love: Emerging Role of CELMoDs (Cereblon E3 Ligase Modulators) and Other Novel Approaches to Targeting Protein Degradation Pathways in Multiple Myeloma

122

What Clinicians Want to Know About Toxicity Considerations Associated with BTK Inhibitors

123

Inside the Issue: The Current and Future Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma

124

Oncology Today with Dr Neil Love: Role of BTK Inhibitors in Patients with Mantle Cell Lymphoma

125

Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 2 of a 2-Part Series

126

Oncology Today with Dr Neil Love: Special Edition — Key Presentations on Chronic Lymphocytic Leukemia and Lymphoma from Recent Major Oncology/Hematology Conferences

127

Inside the Issue: Integrating Bispecific Antibodies into the Management of Multiple Myeloma — Patient Selection and Toxicity Management

128

Oncology Today with Dr Neil Love: Special Edition — What I Tell My Patients About New Treatments and Clinical Trials in Chronic Lymphocytic Leukemia

129

Inside the Issue: Novel Agents, Approaches and Strategies in the Management of Higher-Risk Myelodysplastic Syndromes

130

Oncology Today with Dr Neil Love: Immune Thrombocytopenia Edition

131

Oncology Today with Dr Neil Love: Management of Paroxysmal Nocturnal Hemoglobinuria

132

Meet The Professor: The Current and Future Management of Non-Hodgkin Lymphoma

133

Meet The Professor: Optimizing the Management of Soft Tissue Sarcoma and Related Connective Tissue Disorders — Part 1 of a 2-Part Series

134

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Acute Myeloid Leukemia and Myelodysplastic Syndromes

135

Oncology Today with Dr Neil Love: Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Multiple Myeloma Edition

136

Oncology Today with Dr Neil Love — Key Presentations from the 64th American Society of Hematology (ASH) Annual Meeting: Chronic Lymphocytic Leukemia Edition

137

Recent Advances and Future Directions in Chronic Lymphocytic Leukemia and Lymphomas — With Dr Danielle Brander and Craig Moskowitz (Proceedings from a Symposium in Partnership with NCOA and SCOS)

138

Oncology Today with Dr Neil Love: Key Presentations in Hodgkin and Non-Hodgkin Lymphomas from the 2022 ASH Annual Meeting

139

Inside the Issue — Optimizing the Management of Adverse Events Associated with BTK Inhibitors

140

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hodgkin and Non-Hodgkin Lymphomas

141

Meet The Professor: Optimizing the Management of Multiple Myeloma — Part 4 of a 4-Part Series

142

Oncology Today with Dr Neil Love: Key Presentations on Myeloproliferative Neoplasms from the 2022 ASH Annual Meeting

143

Oncology Today with Dr Neil Love: Advances in Diffuse Large B-Cell Lymphoma

144

Oncology Today with Dr Neil Love: Key Presentations in Acute Myeloid Leukemia and Myelodysplastic Syndromes from the 2022 ASH Annual Meeting

145

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Multiple Myeloma

146

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia

147

Meet The Professor: Optimizing the Management of Multiple Myeloma — Part 3 of a 4-Part Series

148

What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of Acute Myeloid Leukemia